<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009293</url>
  </required_header>
  <id_info>
    <org_study_id>NL44729.078.13</org_study_id>
    <nct_id>NCT02009293</nct_id>
  </id_info>
  <brief_title>The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>Cough-IPF</acronym>
  <official_title>Observational Study of the Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we evaluate the effect of Pirfenidone on cough and quality of life in patients&#xD;
      with idiopathic pulmonary fibrosis (IPF) that are treated with Pirfenidone in daily practice.&#xD;
      The hypothesis is that Pirfenidone will decrease cough and increase quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease of&#xD;
      unknown cause with a median survival of 3-5 years. No curative treatment exists, though in&#xD;
      2011 Pirfenidone was approved for the treatment of IPF as it appeared to slow down the&#xD;
      decline in lung function. In patients with IPF, the most common symptoms are cough and&#xD;
      breathlessness. Cough is not only a major distressing and disabling symptom but also an&#xD;
      independent predictor of disease progression and death in IPF. Recent preliminary data&#xD;
      suggest a possible effect of Pirfenidone on cough.&#xD;
&#xD;
      Objective: In this study we want to objectively measure the effect of Pirfenidone on cough in&#xD;
      patients with IPF that are treated with Pirfenidone in daily practice .&#xD;
&#xD;
      Study design: This is a prospective, observational, international multicenter study.&#xD;
&#xD;
      Intervention: Objective 24-hour cough frequency will be recorded using the Leicester Cough&#xD;
      Monitor (LCM), a validated ambulatory cough monitoring system, prior to starting with&#xD;
      Pirfenidone treatment. The cough recording will be repeated at 4 weeks and at 12 weeks during&#xD;
      treatment with Pirfenidone. At the days of cough recording, patients will be asked to fill in&#xD;
      questionnaires related to cough and to quality of life. Patient will be treated according to&#xD;
      normal clinical practice at their Physician's discretion.&#xD;
&#xD;
      Main study parameters/endpoints: The primary endpoint is change in cough frequency measured&#xD;
      by the Leicester cough monitor at week 12 compared to baseline. Secondary endpoints look at&#xD;
      the relationships between cough, change in cough, quality of life and clinical parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cough frequency measured by cough recorder at week 12 compared to baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of cough on quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cough frequency measured by cough recorder at 4 weeks compared to baseline</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Leicester Cough Questionnaire at week 12 compared to baseline</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Visual Analogue Score at week 12 compared to baseline</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cough frequency in relation to FVC</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristics predictive of cough response</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Impact of cough on anxiety and depression</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cough frequency in relation to TLCOc</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cough IPF</arm_group_label>
    <description>Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cough monitor</intervention_name>
    <description>questionnaires about cough and quality of life</description>
    <arm_group_label>Cough IPF</arm_group_label>
    <other_name>cough monitoring</other_name>
    <other_name>Leicester Cough Monitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with IPF about to start on Pirfenidone according to regular practice in the&#xD;
        participating University Hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IPF according to American Thoracic Society (ATS) / European Respiratory&#xD;
             Society (ERS) criteria (5), definite and probable patients will be eligible&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Daily cough related to IPF (exclusion of other causes) present &gt; 8 weeks&#xD;
&#xD;
          -  cough score on visual analogue scale of ≥ 40 mm.&#xD;
&#xD;
          -  Carbon monoxide transfer capacity corrected for hemoglobin (TLCOc) ≥ 30% and Forced&#xD;
             Vital Capacity (FVC) ≥ 50%&#xD;
&#xD;
          -  Pirfenidone therapy about to be initiated&#xD;
&#xD;
          -  if a history positive for Gastro Esophageal Reflux (GER), using proton pump inhibitor&#xD;
             (PPI) &gt; 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opiates, antitussive medication, antihistamines, steroids &gt; equivalent of 10 mg&#xD;
             prednisone or N-acetylcysteine (NAC) within two weeks before study&#xD;
&#xD;
          -  Change of steroid &lt; 10 mg, inhalation steroids within 2 weeks of the study - History&#xD;
             of bronchial hyper responsiveness or asthma or relevant airway obstruction (FEV1/FVC &lt;&#xD;
             0.7)&#xD;
&#xD;
          -  within 6 weeks of the start signs of respiratory tract infection, change of sputum&#xD;
             production and fever.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. S. Wijsenbeek, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Centre Rotterdam, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. Vancheri, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catania, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V. Cottin, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louis Pradel hospital, Lyon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S Birring, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Medicine,King's College Hospital.Denmark Hill, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Russell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E Renzoni, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Lyon 1, Louis Pradel hospital, Lyon. FranceService de pneumologie, hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Centre for Rare Lung Disease University of Catania.</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Rotterdam, Dep. of Pulmonology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 1, 2013</study_first_submitted>
  <study_first_submitted_qc>December 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Marlies Wijsenbeek</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>idiopathic pulmonary fibrosis</keyword>
  <keyword>cough</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

